Key Ranolazine patent for CV Therapeutics/Gilead: a novel class of compounds that are useful in the treatment of cardiovascular diseases including arrhythmias, angina, congestive heart disease, and myocardial infarction.

Key CV Therapeutics/Gilead patent for A2A receptor agonists to stimulate mammalian coronary vasodilatation for therapeutic purposes and for purposes of imaging the heart.

Key Ranolazine patent for CV Therapeutics/Gilead: a novel class of compounds that are useful in the treatment of cardiovascular diseases including arrhythmias, angina, congestive heart disease, and myocardial infarction.